Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Non-Hodgkin Lymphoma through trial conditions or approval indications mapped to it or to one of its descendant entities.
45 drugs · 284 active trials
27 drugs · 479 active trials
56 drugs · 2,316 active trials
Outside the funnel: Phase not stated 1 · Withdrawn 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 11 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Ruxolitinib | Phase 2 | Phase 2 | 13 | 12 | 0 | 20 | 0 | — | — | 2008-03 |
| Thiotepa | Phase 2 | Phase 2 | 10 | 3 | 0 | 28 | 0 | — | — | 2003-04 |
| Nirogacestat | Phase 2 | Phase 2 | 8 | 2 | 0 | 10 | 0 | — | — | Sep 23, 2019 |
| Atezolizumab | Phase 2 | Phase 2 | 5 | 0 | 0 | 17 | 0 | — | — | Sep 15, 2015 |
| Palbociclib | Phase 2 | Phase 2 | 5 | 1 | 0 | 13 | 0 | — | — | 2004-09 |
| Cemiplimab | Phase 2 | Phase 2 | 5 | 4 | 0 | 6 | 0 | — | — | Apr 4, 2017 |
| Durvalumab | Phase 2 | Phase 2 | 4 | 3 | 0 | 19 | 0 | — | — | 2015-05 |
| Sintilimab | Phase 2 | Phase 2 | 4 | 2 | 0 | 10 | 0 | — | — | Nov 1, 2019 |
| Sunitinib | Phase 2 | Phase 2 | 4 | 2 | 0 | 9 | 0 | — | — | 2006-09 |
| Abexinostat | Phase 2 | Phase 2 | 4 | 1 | 0 | 8 | 0 | — | — | 2007-11 |
| Paclitaxel | Phase 2 | Phase 2 | 4 | 3 | 0 | 8 | 0 | — | — | May 18, 2001 |
| Binimetinib | Phase 2 | Phase 2 | 4 | 1 | 0 | 5 | 0 | — | — | Aug 17, 2015 |
| Erdafitinib | Phase 2 | Phase 2 | 4 | 0 | 0 | 5 | 0 | — | — | Aug 17, 2015 |
| Larotrectinib | Phase 2 | Phase 2 | 4 | 0 | 0 | 4 | 0 | — | — | Aug 17, 2015 |
| Clofarabine | Phase 2 | Phase 2 | 3 | 3 | 0 | 22 | 0 | — | — | 2004-10 |
| Temozolomide | Phase 2 | Phase 2 | 3 | 3 | 0 | 9 | 0 | — | — | 2006-11 |
| Tislelizumab | Phase 2 | Phase 2 | 3 | 1 | 0 | 9 | 0 | — | — | Apr 13, 2018 |
| Tretinoin | Phase 2 | Phase 2 | 3 | 2 | 0 | 8 | 0 | — | — | 2013-12 |
| Olaparib | Phase 2 | Phase 2 | 3 | 2 | 0 | 6 | 0 | — | — | Mar 14, 2016 |
| Vismodegib | Phase 2 | Phase 2 | 3 | 1 | 0 | 6 | 0 | — | — | 2010-12 |
| Brexucabtagene Autoleucel | Phase 2 | Phase 2 | 3 | 3 | 0 | 5 | 0 | — | — | Nov 9, 2015 |
| Pemetrexed | Phase 2 | Phase 2 | 3 | 1 | 0 | 5 | 0 | — | — | 2009-02 |
| Afatinib | Phase 2 | Phase 2 | 3 | 0 | 0 | 4 | 0 | — | — | Aug 12, 2015 |
| Sapanisertib | Phase 2 | Phase 2 | 3 | 0 | 0 | 4 | 0 | — | — | 2010-11 |
| Radiation Therapy | Phase 2 | Phase 2 | 3 | 1 | 0 | 3 | 0 | — | — | Feb 4, 2019 |
| Camrelizumab | Phase 2 | Phase 2 | 2 | 2 | 0 | 9 | 0 | — | — | May 1, 2017 |
| Tipifarnib | Phase 2 | Phase 2 | 2 | 0 | 0 | 6 | 0 | — | — | Mar 24, 2004 |
| Pacritinib | Phase 2 | Phase 2 | 2 | 2 | 0 | 5 | 0 | — | — | 2010-12 |
| Enzalutamide | Phase 2 | Phase 2 | 2 | 2 | 0 | 4 | 0 | — | — | Aug 11, 2015 |
| Treosulfan | Phase 2 | Phase 2 | 2 | 2 | 0 | 4 | 0 | — | — | 2005-09 |
| Ponatinib | Phase 2 | Phase 2 | 2 | 2 | 0 | 3 | 0 | — | — | Apr 1, 2020 |
| Taselisib | Phase 2 | Phase 2 | 2 | 0 | 0 | 3 | 0 | — | — | Mar 16, 2011 |
| Trastuzumab Emtansine | Phase 2 | Phase 2 | 2 | 0 | 0 | 3 | 0 | — | — | Aug 12, 2015 |
| Adavosertib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Capivasertib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Ensartinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2017 |
| Ipatasertib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Ivosidenib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2017 |
| Osimertinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Selpercatinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2017 |
| Metformin | Phase 2 | Phase 2 | 1 | 0 | 0 | 8 | 0 | — | — | 2015-07 |
| Nab-paclitaxel | Phase 2 | Phase 2 | 1 | 0 | 0 | 7 | 0 | — | — | Nov 5, 2012 |
| Abemaciclib | Phase 2 | Phase 2 | 1 | 1 | 0 | 5 | 0 | — | — | Jul 31, 2012 |
| Irinotecan | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 1999-01 |
| Navtemadlin | Phase 2 | Phase 2 | 1 | 1 | 0 | 4 | 0 | — | — | Dec 27, 2012 |
| Procarbazine | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | Dec 8, 2014 |
| Trastuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | Feb 27, 2015 |
| Enasidenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Dec 8, 2014 |
| Samotolisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Jul 31, 2012 |
| Selumetinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2010-03 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.